{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:48:29Z","timestamp":1781106509677,"version":"3.54.1"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12012-024-09952-4","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T02:02:40Z","timestamp":1736906560000},"page":"248-268","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Doxorubicin or Epirubicin Versus Liposomal Doxorubicin Therapy\u2014Differences in Cardiotoxicity"],"prefix":"10.1007","volume":"25","author":[{"given":"Barbara","family":"Buchalska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Kami\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Kowara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Sobiborowicz-Sadowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Cudnoch-J\u0119drzejewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"issue":"6","key":"9952_CR1","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00204-022-03262-w","volume":"96","author":"NF Sangweni","year":"2022","unstructured":"Sangweni, N. F., Gabuza, K., Huisamen, B., Mabasa, L., van Vuuren, D., & Johnson, R. (2022). Molecular insights into the pathophysiology of doxorubicin-induced cardiotoxicity: A graphical representation. Archives of Toxicology, 96(6), 1541\u20131550. https:\/\/doi.org\/10.1007\/s00204-022-03262-w","journal-title":"Archives of Toxicology"},{"issue":"6","key":"9952_CR2","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/bit.260110607","volume":"11","author":"F Arcamone","year":"1969","unstructured":"Arcamone, F., Cassinelli, G., Fantini, G., Grein, A., Orezzi, P., Pol, C., & Spalla, C. (1969). Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnology and bioengineering, 11(6), 1101\u20131110. https:\/\/doi.org\/10.1002\/bit.260110607","journal-title":"Biotechnology and bioengineering"},{"key":"9952_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031912","author":"BB Wu","year":"2022","unstructured":"Wu, B. B., Leung, K. T., & Poon, E. N. (2022). Mitochondrial-targeted therapy for doxorubicin-induced cardiotoxicity. International journal of molecular sciences. https:\/\/doi.org\/10.3390\/ijms23031912","journal-title":"International journal of molecular sciences"},{"issue":"2","key":"9952_CR4","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.drudis.2016.11.005","volume":"22","author":"M Cagel","year":"2017","unstructured":"Cagel, M., Grotz, E., Bernabeu, E., Moretton, M. A., & Chiappetta, D. A. (2017). Doxorubicin: Nanotechnological overviews from bench to bedside. Drug Discovery Today, 22(2), 270\u2013281. https:\/\/doi.org\/10.1016\/j.drudis.2016.11.005","journal-title":"Drug Discovery Today"},{"key":"9952_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.lfs.2018.03.023","volume":"200","author":"A Pugazhendhi","year":"2018","unstructured":"Pugazhendhi, A., Edison, T. N. J. I., Velmurugan, B. K., Jacob, J. A., & Karuppusamy, I. (2018). Toxicity of doxorubicin (Dox) to different experimental organ systems. Life Sciences, 200, 26\u201330. https:\/\/doi.org\/10.1016\/j.lfs.2018.03.023","journal-title":"Life Sciences"},{"key":"9952_CR6","doi-asserted-by":"publisher","first-page":"120117","DOI":"10.1016\/j.ijpharm.2020.120117","volume":"593","author":"V Makwana","year":"2021","unstructured":"Makwana, V., Karanjia, J., Haselhorst, T., Anoopkumar-Dukie, S., & Rudrawar, S. (2021). Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization. International Journal of Pharmaceutics, 593, 120117. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.120117","journal-title":"International Journal of Pharmaceutics"},{"issue":"2","key":"9952_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.5603\/CJ.a2020.0062","volume":"29","author":"R Mata Caballero","year":"2022","unstructured":"Mata Caballero, R., Serrano Antol\u00edn, J. M., Jim\u00e9nez Hern\u00e1ndez, R. M., Talavera Calle, P., Curcio Ruig\u00f3mez, A., Del Castillo Arrojo, S., Graupner Abad, C., Crist\u00f3bal Varela, C., & Alonso Mart\u00edn, J. J. (2022). Incidence of long-term cardiotoxicity and evolution of the systolic function in patients with breast cancer treated with anthracyclines. Cardiology Journal, 29(2), 228\u2013234. https:\/\/doi.org\/10.5603\/CJ.a2020.0062","journal-title":"Cardiology Journal"},{"key":"9952_CR8","volume-title":"Cardiotoxicity","author":"DS dos Santos","year":"2018","unstructured":"dos Santos, D. S., & dos Santos Goldenberg, R. C. (2018). Doxorubicin-induced cardiotoxicity: From mechanisms to development of efficient therapy. In T. Wenyong (Ed.), Cardiotoxicity. IntechOpen."},{"key":"9952_CR9","doi-asserted-by":"crossref","unstructured":"Aloss, K., & Hamar, P. (2023). Recent preclinical and clinical progress in liposomal doxorubicin. Pharmaceutics, 15(3), 893. https:\/\/www.mdpi.com\/1999-4923\/15\/3\/893","DOI":"10.3390\/pharmaceutics15030893"},{"key":"9952_CR10","doi-asserted-by":"publisher","unstructured":"Lyon, A. R., L\u00f3pez-Fern\u00e1ndez, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., Cutter, D. J., de Azambuja, E., de Boer, R. A., Dent, S. F., Farmakis, D., Gevaert, S. A., Gorog, D. A., Herrmann, J., Lenihan, D., . . . Group, E. S. D. (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). European Heart Journal, 43(41), 4229-4361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"9952_CR11","doi-asserted-by":"publisher","first-page":"117954681986644","DOI":"10.1177\/1179546819866445","volume":"13","author":"IE Perez","year":"2019","unstructured":"Perez, I. E., Taveras Alam, S., Hernandez, G. A., & Sancassani, R. (2019). Cancer therapy-related cardiac dysfunction: An overview for the clinician. Clinical Medicine Insights: Cardiology, 13, 1179546819866445. https:\/\/doi.org\/10.1177\/1179546819866445","journal-title":"Clinical Medicine Insights: Cardiology"},{"issue":"1","key":"9952_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40959-020-00079-3","volume":"6","author":"JAM Kamphuis","year":"2020","unstructured":"Kamphuis, J. A. M., Linschoten, M., Cramer, M. J., Doevendans, P. A., Asselbergs, F. W., & Teske, A. J. (2020). Early- and late anthracycline-induced cardiac dysfunction: Echocardiographic characterization and response to heart failure therapy. Cardio-Oncology, 6(1), 23. https:\/\/doi.org\/10.1186\/s40959-020-00079-3","journal-title":"Cardio-Oncology"},{"issue":"1","key":"9952_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1080\/21548331.2018.1530831","volume":"47","author":"D Jain","year":"2019","unstructured":"Jain, D., & Aronow, W. (2019). Cardiotoxicity of cancer chemotherapy in clinical practice. Hospital Practice (1995), 47(1), 6\u201315. https:\/\/doi.org\/10.1080\/21548331.2018.1530831","journal-title":"Hospital Practice (1995)"},{"issue":"5","key":"9952_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1200\/op.20.00924","volume":"17","author":"JR Stone","year":"2021","unstructured":"Stone, J. R., Kanneganti, R., Abbasi, M., & Akhtari, M. (2021). Monitoring for chemotherapy-related cardiotoxicity in the form of left ventricular systolic dysfunction: A review of current recommendations. JCO Oncology Practice, 17(5), 228\u2013236. https:\/\/doi.org\/10.1200\/op.20.00924","journal-title":"JCO Oncology Practice"},{"issue":"22","key":"9952_CR15","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/circulationaha.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale, D., Colombo, A., Bacchiani, G., Tedeschi, I., Meroni, C. A., Veglia, F., Civelli, M., Lamantia, G., Colombo, N., Curigliano, G., Fiorentini, C., & Cipolla, C. M. (2015). Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation, 131(22), 1981\u20131988. https:\/\/doi.org\/10.1161\/circulationaha.114.013777","journal-title":"Circulation"},{"issue":"1","key":"9952_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/toxsci\/kfu057","volume":"140","author":"L Cove-Smith","year":"2014","unstructured":"Cove-Smith, L., Woodhouse, N., Hargreaves, A., Kirk, J., Smith, S., Price, S. A., Galvin, M., Betts, C. J., Brocklehurst, S., Backen, A., Radford, J., Linton, K., Roberts, R. A., Schmitt, M., Dive, C., Tugwood, J. D., Hockings, P. D., & Mellor, H. R. (2014). An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity. Toxicological Sciences, 140(1), 3\u201315. https:\/\/doi.org\/10.1093\/toxsci\/kfu057","journal-title":"Toxicological Sciences"},{"issue":"2","key":"9952_CR17","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2","volume":"32","author":"EA Lefrak","year":"1973","unstructured":"Lefrak, E. A., Pitha, J., Rosenheim, S., & Gottlieb, J. A. (1973). A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer, 32(2), 302\u2013314. https:\/\/doi.org\/10.1002\/1097-0142(197308)32:2%3c302::aid-cncr2820320205%3e3.0.co;2-2","journal-title":"Cancer"},{"issue":"2","key":"9952_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jjcc.2019.02.001","volume":"74","author":"DY Kim","year":"2019","unstructured":"Kim, D. Y., Youn, J.-C., Park, M.-S., Lee, S., Choi, S.-W., Ryu, K.-H., Kim, L. S., Shim, M.-S., Lee, J. J., & Han, S. (2019). Cardiovascular outcome of breast cancer patients with concomitant radiotherapy and chemotherapy: A 10-year multicenter cohort study. Journal of Cardiology, 74(2), 175\u2013181. https:\/\/doi.org\/10.1016\/j.jjcc.2019.02.001","journal-title":"Journal of Cardiology"},{"key":"9952_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1200\/edbk_100015","volume":"38","author":"S Armenian","year":"2018","unstructured":"Armenian, S., & Bhatia, S. (2018). Predicting and preventing anthracycline-related cardiotoxicity. American Society of Clinical Oncology Educational Book, 38, 3\u201312. https:\/\/doi.org\/10.1200\/edbk_100015","journal-title":"American Society of Clinical Oncology Educational Book"},{"issue":"1","key":"9952_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40959-021-00101-2","volume":"7","author":"T Mohammed","year":"2021","unstructured":"Mohammed, T., Singh, M., Tiu, J. G., & Kim, A. S. (2021). Etiology and management of hypertension in patients with cancer. Cardio-Oncology, 7(1), 14. https:\/\/doi.org\/10.1186\/s40959-021-00101-2","journal-title":"Cardio-Oncology"},{"key":"9952_CR21","doi-asserted-by":"publisher","first-page":"736854","DOI":"10.3389\/fcvm.2021.736854","volume":"8","author":"S Qiu","year":"2021","unstructured":"Qiu, S., Zhou, T., Qiu, B., Zhang, Y., Zhou, Y., Yu, H., Zhang, J., Liu, L., Yuan, L., Yang, G., Duan, Y., & Xing, C. (2021). Risk factors for anthracycline-induced cardiotoxicity. Front Cardiovasc Med, 8, 736854. https:\/\/doi.org\/10.3389\/fcvm.2021.736854","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"9952_CR22","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jacbts.2018.06.005","volume":"3","author":"AZ Luu","year":"2018","unstructured":"Luu, A. Z., Chowdhury, B., Al-Omran, M., Teoh, H., Hess, D. A., & Verma, S. (2018). Role of endothelium in doxorubicin-induced cardiomyopathy. JACC Basic to Translational Science, 3(6), 861\u2013870. https:\/\/doi.org\/10.1016\/j.jacbts.2018.06.005","journal-title":"JACC Basic to Translational Science"},{"issue":"3","key":"9952_CR23","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/cphy.c180017","volume":"9","author":"TR Mancilla","year":"2019","unstructured":"Mancilla, T. R., Iskra, B., & Aune, G. J. (2019). Doxorubicin-induced cardiomyopathy in children. Comprehensive Physiology, 9(3), 905\u2013931. https:\/\/doi.org\/10.1002\/cphy.c180017","journal-title":"Comprehensive Physiology"},{"issue":"2","key":"9952_CR24","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdq609","volume":"22","author":"M Aapro","year":"2011","unstructured":"Aapro, M., Bernard-Marty, C., Brain, E. G. C., Batist, G., Erdkamp, F., Krzemieniecki, K., Leonard, R., Lluch, A., Monfardini, S., Ryberg, M., Soubeyran, P., & Wedding, U. (2011). Anthracycline cardiotoxicity in the elderly cancer patient: A SIOG expert position paper. Annals of Oncology, 22(2), 257\u2013267. https:\/\/doi.org\/10.1093\/annonc\/mdq609","journal-title":"Annals of Oncology"},{"issue":"9","key":"9952_CR25","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1093\/jn\/nxaa144","volume":"150","author":"CY Asselin","year":"2020","unstructured":"Asselin, C. Y., Lam, A., Cheung, D. Y. C., Eekhoudt, C. R., Zhu, A., Mittal, I., Mayba, A., Solati, Z., Edel, A., Austria, J. A., Aukema, H. M., Ravandi, A., Thliveris, J., Singal, P. K., Pierce, G. N., Niraula, S., & Jassal, D. S. (2020). The cardioprotective role of flaxseed in the prevention of doxorubicin- and trastuzumab-mediated cardiotoxicity in C57BL\/6 Mice. The Journal of Nutrition, 150(9), 2353\u20132363. https:\/\/doi.org\/10.1093\/jn\/nxaa144","journal-title":"The Journal of Nutrition"},{"key":"9952_CR26","doi-asserted-by":"publisher","first-page":"119760","DOI":"10.1016\/j.lfs.2021.119760","volume":"280","author":"M Anjos","year":"2021","unstructured":"Anjos, M., Fontes-Oliveira, M., Costa, V. M., Santos, M., & Ferreira, R. (2021). An update of the molecular mechanisms underlying doxorubicin plus trastuzumab induced cardiotoxicity. Life Sciences, 280, 119760. https:\/\/doi.org\/10.1016\/j.lfs.2021.119760","journal-title":"Life Sciences"},{"issue":"2","key":"9952_CR27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","volume":"65","author":"O Tacar","year":"2012","unstructured":"Tacar, O., Sriamornsak, P., & Dass, C. R. (2012). Doxorubicin: An update on anticancer molecular action, toxicity and novel drug delivery systems. Journal of Pharmacy and Pharmacology, 65(2), 157\u2013170. https:\/\/doi.org\/10.1111\/j.2042-7158.2012.01567.x","journal-title":"Journal of Pharmacy and Pharmacology"},{"issue":"3","key":"9952_CR28","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/jphp.12869","volume":"70","author":"M Baxter-Holland","year":"2018","unstructured":"Baxter-Holland, M., & Dass, C. R. (2018). Doxorubicin, mesenchymal stem cell toxicity and antitumour activity: Implications for clinical use. Journal of Pharmacy and Pharmacology, 70(3), 320\u2013327. https:\/\/doi.org\/10.1111\/jphp.12869","journal-title":"Journal of Pharmacy and Pharmacology"},{"issue":"8","key":"9952_CR29","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0961203314565413","volume":"24","author":"VL Souliotis","year":"2015","unstructured":"Souliotis, V. L., & Sfikakis, P. P. (2015). Increased DNA double-strand breaks and enhanced apoptosis in patients with lupus nephritis. Lupus, 24(8), 804\u2013815. https:\/\/doi.org\/10.1177\/0961203314565413","journal-title":"Lupus"},{"issue":"12","key":"9952_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2020.129720","volume":"1864","author":"E Bilgen","year":"2020","unstructured":"Bilgen, E., & Persil \u00c7etinkol, \u00d6. (2020). Doxorubicin exhibits strong and selective association with VEGF Pu(22) G-quadruplex. Biochimica et Biophysica Acta - General Subjects, 1864(12), 129720. https:\/\/doi.org\/10.1016\/j.bbagen.2020.129720","journal-title":"Biochimica et Biophysica Acta - General Subjects"},{"key":"9952_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/bip.22998","author":"EF Silva","year":"2017","unstructured":"Silva, E. F., Bazoni, R. F., Ramos, E. B., & Rocha, M. S. (2017). DNA-doxorubicin interaction: New insights and peculiarities. Biopolymers. https:\/\/doi.org\/10.1002\/bip.22998","journal-title":"Biopolymers"},{"issue":"1","key":"9952_CR32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bbcan.2013.12.002","volume":"1845","author":"F Yang","year":"2014","unstructured":"Yang, F., Teves, S. S., Kemp, C. J., & Henikoff, S. (2014). Doxorubicin, DNA torsion, and chromatin dynamics. Biochimica et Biophysica Acta, 1845(1), 84\u201389. https:\/\/doi.org\/10.1016\/j.bbcan.2013.12.002","journal-title":"Biochimica et Biophysica Acta"},{"key":"9952_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/genes10110859","author":"JH Lee","year":"2019","unstructured":"Lee, J. H., & Berger, J. M. (2019). Cell cycle-dependent control and roles of DNA topoisomerase II. Genes (Basel). https:\/\/doi.org\/10.3390\/genes10110859","journal-title":"Genes (Basel)"},{"issue":"8","key":"9952_CR34","doi-asserted-by":"publisher","first-page":"5757","DOI":"10.1021\/acs.joc.1c00220","volume":"86","author":"DPA Wander","year":"2021","unstructured":"Wander, D. P. A., van der Zanden, S. Y., Vriends, M. B. L., van Veen, B. C., Vlaming, J. G. C., Bruyning, T., Hansen, T., van der Marel, G. A., Overkleeft, H. S., Neefjes, J. J. C., & Cod\u00e9e, J. D. C. (2021). Synthetic (N, N-Dimethyl)doxorubicin glycosyl diastereomers to dissect modes of action of anthracycline anticancer drugs. Journal of Organic Chemistry, 86(8), 5757\u20135770. https:\/\/doi.org\/10.1021\/acs.joc.1c00220","journal-title":"Journal of Organic Chemistry"},{"issue":"21","key":"9952_CR35","doi-asserted-by":"publisher","first-page":"12814","DOI":"10.1021\/acs.jmedchem.0c01191","volume":"63","author":"DPA Wander","year":"2020","unstructured":"Wander, D. P. A., van der Zanden, S. Y., van der Marel, G. A., Overkleeft, H. S., Neefjes, J., & Cod\u00e9e, J. D. C. (2020). Doxorubicin and aclarubicin: Shuffling anthracycline glycans for improved anticancer agents. Journal of Medicinal Chemistry, 63(21), 12814\u201312829. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01191","journal-title":"Journal of Medicinal Chemistry"},{"key":"9952_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.toxlet.2019.02.013","volume":"307","author":"M Songbo","year":"2019","unstructured":"Songbo, M., Lang, H., Xinyong, C., Bin, X., Ping, Z., & Liang, S. (2019). Oxidative stress injury in doxorubicin-induced cardiotoxicity. Toxicology Letters, 307, 41\u201348. https:\/\/doi.org\/10.1016\/j.toxlet.2019.02.013","journal-title":"Toxicology Letters"},{"key":"9952_CR37","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.redox.2017.12.013","volume":"15","author":"L Zhao","year":"2018","unstructured":"Zhao, L., Qi, Y., Xu, L., Tao, X., Han, X., Yin, L., & Peng, J. (2018). MicroRNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting Nrf2 and Sirt2. Redox Biology, 15, 284\u2013296. https:\/\/doi.org\/10.1016\/j.redox.2017.12.013","journal-title":"Redox Biology"},{"issue":"2","key":"9952_CR38","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3892\/ijo.2016.3558","volume":"49","author":"N Pilco-Ferreto","year":"2016","unstructured":"Pilco-Ferreto, N., & Calaf, G. M. (2016). Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines. International Journal of Oncology, 49(2), 753\u2013762. https:\/\/doi.org\/10.3892\/ijo.2016.3558","journal-title":"International Journal of Oncology"},{"issue":"6","key":"9952_CR39","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/jphp.12539","volume":"68","author":"AM Meredith","year":"2016","unstructured":"Meredith, A. M., & Dass, C. R. (2016). Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism. Journal of Pharmacy and Pharmacology, 68(6), 729\u2013741. https:\/\/doi.org\/10.1111\/jphp.12539","journal-title":"Journal of Pharmacy and Pharmacology"},{"key":"9952_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tiv.2018.05.001","volume":"51","author":"J Yin","year":"2018","unstructured":"Yin, J., Guo, J., Zhang, Q., Cui, L., Zhang, L., Zhang, T., Zhao, J., Li, J., Middleton, A., Carmichael, P. L., & Peng, S. (2018). Doxorubicin-induced mitophagy and mitochondrial damage is associated with dysregulation of the PINK1\/parkin pathway. Toxicology in Vitro, 51, 1\u201310. https:\/\/doi.org\/10.1016\/j.tiv.2018.05.001","journal-title":"Toxicology in Vitro"},{"key":"9952_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/cells11132000","author":"L Schirone","year":"2022","unstructured":"Schirone, L., D\u2019Ambrosio, L., Forte, M., Genovese, R., Schiavon, S., Spinosa, G., Iacovone, G., Valenti, V., Frati, G., & Sciarretta, S. (2022). Mitochondria and doxorubicin-induced cardiomyopathy: A complex interplay. Cells. https:\/\/doi.org\/10.3390\/cells11132000","journal-title":"Cells"},{"key":"9952_CR42","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.132747","author":"T Tadokoro","year":"2020","unstructured":"Tadokoro, T., Ikeda, M., Ide, T., Deguchi, H., Ikeda, S., Okabe, K., Ishikita, A., Matsushima, S., Koumura, T., Yamada, K. I., Imai, H., & Tsutsui, H. (2020). Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.132747","journal-title":"JCI Insight"},{"issue":"7","key":"9952_CR43","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1161\/circresaha.119.314681","volume":"126","author":"KB Wallace","year":"2020","unstructured":"Wallace, K. B., Sard\u00e3o, V. A., & Oliveira, P. J. (2020). Mitochondrial determinants of doxorubicin-induced cardiomyopathy. Circulation Research, 126(7), 926\u2013941. https:\/\/doi.org\/10.1161\/circresaha.119.314681","journal-title":"Circulation Research"},{"issue":"18","key":"9952_CR44","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.1158\/1078-0432.Ccr-13-3373","volume":"20","author":"S Khiati","year":"2014","unstructured":"Khiati, S., Dalla Rosa, I., Sourbier, C., Ma, X., Rao, V. A., Neckers, L. M., Zhang, H., & Pommier, Y. (2014). Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity. Clinical Cancer Research, 20(18), 4873\u20134881. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-3373","journal-title":"Clinical Cancer Research"},{"key":"9952_CR45","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ejphar.2017.10.043","volume":"818","author":"K Renu","year":"2018","unstructured":"Renu, K., Abilash, V. G., PB, T. P., & Arunachalam, S. (2018). Molecular mechanism of doxorubicin-induced cardiomyopathy - an update. European journal of pharmacology, 818, 241\u2013253. https:\/\/doi.org\/10.1016\/j.ejphar.2017.10.043","journal-title":"European journal of pharmacology"},{"issue":"2","key":"9952_CR46","doi-asserted-by":"publisher","first-page":"e0172803","DOI":"10.1371\/journal.pone.0172803","volume":"12","author":"MC Asensio-L\u00f3pez","year":"2017","unstructured":"Asensio-L\u00f3pez, M. C., Soler, F., Pascual-Figal, D., Fern\u00e1ndez-Belda, F., & Lax, A. (2017). Doxorubicin-induced oxidative stress: The protective effect of nicorandil on HL-1 cardiomyocytes. PLoS ONE, 12(2), e0172803. https:\/\/doi.org\/10.1371\/journal.pone.0172803","journal-title":"PLoS ONE"},{"key":"9952_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-021-07252-5","author":"Y Wan","year":"2021","unstructured":"Wan, Y., He, B., Zhu, D., Wang, L., Huang, R., Wang, S., Wang, C., Zhang, M., Ma, L., & Gao, F. (2021). Nicorandil Ameliorates doxorubicin-induced cardiotoxicity in rats, as evaluated by 7 T cardiovascular magnetic resonance imaging. Cardiovascular Drugs and Therapy. https:\/\/doi.org\/10.1007\/s10557-021-07252-5","journal-title":"Cardiovascular Drugs and Therapy"},{"issue":"2","key":"9952_CR48","doi-asserted-by":"publisher","first-page":"R227","DOI":"10.1152\/ajpregu.00299.2019","volume":"318","author":"RN Montalvo","year":"2020","unstructured":"Montalvo, R. N., Doerr, V., Min, K., Szeto, H. H., & Smuder, A. J. (2020). Doxorubicin-induced oxidative stress differentially regulates proteolytic signaling in cardiac and skeletal muscle. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 318(2), R227-r233. https:\/\/doi.org\/10.1152\/ajpregu.00299.2019","journal-title":"American Journal of Physiology: Regulatory, Integrative and Comparative Physiology"},{"issue":"3","key":"9952_CR49","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jaccao.2020.08.005","volume":"2","author":"DB Sawyer","year":"2020","unstructured":"Sawyer, D. B. (2020). Anthracycline-induced vascular dysfunction: Is MitoQ the answer? JACC CardioOncol, 2(3), 489\u2013490. https:\/\/doi.org\/10.1016\/j.jaccao.2020.08.005","journal-title":"JACC CardioOncol"},{"issue":"290","key":"9952_CR50","first-page":"158","volume":"49","author":"M Miedziaszczyk","year":"2021","unstructured":"Miedziaszczyk, M., Cie\u015blewicz, A., & Jab\u0142ecka, A. (2021). Efficacy of coenzyme Q10 in supportive therapy of the cardiovascular diseases and in the prevention of cardiotoxicity caused by chemotherapy. Polski Merkuriusz Lekarski, 49(290), 158\u2013161.","journal-title":"Polski Merkuriusz Lekarski"},{"key":"9952_CR51","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.freeradbiomed.2018.09.043","volume":"133","author":"T Hirschhorn","year":"2019","unstructured":"Hirschhorn, T., & Stockwell, B. R. (2019). The development of the concept of ferroptosis. Free Radical Biology & Medicine, 133, 130\u2013143. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2018.09.043","journal-title":"Free Radical Biology & Medicine"},{"issue":"1","key":"9952_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40959-019-0036-7","volume":"5","author":"S Ganatra","year":"2019","unstructured":"Ganatra, S., Nohria, A., Shah, S., Groarke, J. D., Sharma, A., Venesy, D., Patten, R., Gunturu, K., Zarwan, C., Neilan, T. G., Barac, A., Hayek, S. S., Dani, S., Solanki, S., Mahmood, S. S., & Lipshultz, S. E. (2019). Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: A consecutive case series. Cardio-Oncology, 5(1), 1. https:\/\/doi.org\/10.1186\/s40959-019-0036-7","journal-title":"Cardio-Oncology"},{"key":"9952_CR53","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cbi.2019.01.032","volume":"303","author":"N Koleini","year":"2019","unstructured":"Koleini, N., Nickel, B. E., Edel, A. L., Fandrich, R. R., Ravandi, A., & Kardami, E. (2019). Oxidized phospholipids in doxorubicin-induced cardiotoxicity. Chemico-Biological Interactions, 303, 35\u201339. https:\/\/doi.org\/10.1016\/j.cbi.2019.01.032","journal-title":"Chemico-Biological Interactions"},{"issue":"7","key":"9952_CR54","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1073\/pnas.1821022116","volume":"116","author":"X Fang","year":"2019","unstructured":"Fang, X., Wang, H., Han, D., Xie, E., Yang, X., Wei, J., Gu, S., Gao, F., Zhu, N., Yin, X., Cheng, Q., Zhang, P., Dai, W., Chen, J., Yang, F., Yang, H. T., Linkermann, A., Gu, W., Min, J., & Wang, F. (2019). Ferroptosis as a target for protection against cardiomyopathy. Proc Natl Acad Sci U S A, 116(7), 2672\u20132680. https:\/\/doi.org\/10.1073\/pnas.1821022116","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"36","key":"9952_CR55","doi-asserted-by":"publisher","first-page":"e2117396119","DOI":"10.1073\/pnas.2117396119","volume":"119","author":"N Ta","year":"2022","unstructured":"Ta, N., Qu, C., Wu, H., Zhang, D., Sun, T., Li, Y., Wang, J., Wang, X., Tang, T., Chen, Q., & Liu, L. (2022). Mitochondrial outer membrane protein FUNDC2 promotes ferroptosis and contributes to doxorubicin-induced cardiomyopathy. Proceedings of the National Academy of Sciences U S A, 119(36), e2117396119. https:\/\/doi.org\/10.1073\/pnas.2117396119","journal-title":"Proceedings of the National Academy of Sciences U S A"},{"key":"9952_CR56","doi-asserted-by":"publisher","DOI":"10.1007\/s10565-021-09660-7","author":"S Zhuang","year":"2021","unstructured":"Zhuang, S., Ma, Y., Zeng, Y., Lu, C., Yang, F., Jiang, N., Ge, J., Ju, H., Zhong, C., Wang, J., Zhang, J., & Jiang, S. (2021). METTL14 promotes doxorubicin-induced cardiomyocyte ferroptosis by regulating the KCNQ1OT1-miR-7-5p-TFRC axis. Cell Biology and Toxicology. https:\/\/doi.org\/10.1007\/s10565-021-09660-7","journal-title":"Cell Biology and Toxicology"},{"issue":"6","key":"9952_CR57","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s10637-016-0388-x","volume":"34","author":"NE Frank","year":"2016","unstructured":"Frank, N. E., Cusack, B. J., Talley, T. T., Walsh, G. M., & Olson, R. D. (2016). Comparative effects of doxorubicin and a doxorubicin analog, 13-deoxy, 5-iminodoxorubicin (GPX-150), on human topoisomerase II\u03b2 activity and cardiac function in a chronic rabbit model. Investigational New Drugs, 34(6), 693\u2013700. https:\/\/doi.org\/10.1007\/s10637-016-0388-x","journal-title":"Investigational New Drugs"},{"issue":"3","key":"9952_CR58","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00109-016-1494-0","volume":"95","author":"C Kankeu","year":"2017","unstructured":"Kankeu, C., Clarke, K., Passante, E., & Huber, H. J. (2017). Doxorubicin-induced chronic dilated cardiomyopathy-the apoptosis hypothesis revisited. Journal of Molecular Medicine (Berlin, Germany), 95(3), 239\u2013248. https:\/\/doi.org\/10.1007\/s00109-016-1494-0","journal-title":"Journal of Molecular Medicine (Berlin, Germany)"},{"key":"9952_CR59","doi-asserted-by":"publisher","first-page":"15798","DOI":"10.1038\/srep15798","volume":"5","author":"HJ Shin","year":"2015","unstructured":"Shin, H. J., Kwon, H. K., Lee, J. H., Gui, X., Achek, A., Kim, J. H., & Choi, S. (2015). Doxorubicin-induced necrosis is mediated by poly-(ADP-ribose) polymerase 1 (PARP1) but is independent of p53. Science and Reports, 5, 15798. https:\/\/doi.org\/10.1038\/srep15798","journal-title":"Science and Reports"},{"key":"9952_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031414","author":"H Kitakata","year":"2022","unstructured":"Kitakata, H., Endo, J., Ikura, H., Moriyama, H., Shirakawa, K., Katsumata, Y., & Sano, M. (2022). Therapeutic targets for DOX-induced cardiomyopathy: Role of Apoptosis vs. Ferroptosis. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms23031414","journal-title":"International Journal of Molecular Sciences"},{"key":"9952_CR61","doi-asserted-by":"publisher","first-page":"102089","DOI":"10.1016\/j.redox.2021.102089","volume":"46","author":"D Li","year":"2021","unstructured":"Li, D., Yang, Y., Wang, S., He, X., Liu, M., Bai, B., Tian, C., Sun, R., Yu, T., & Chu, X. (2021). Role of acetylation in doxorubicin-induced cardiotoxicity. Redox Biology, 46, 102089. https:\/\/doi.org\/10.1016\/j.redox.2021.102089","journal-title":"Redox Biology"},{"issue":"17","key":"9952_CR62","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1080\/15384101.2018.1520565","volume":"17","author":"RW Lin","year":"2018","unstructured":"Lin, R. W., Ho, C. J., Chen, H. W., Pao, Y. H., Chen, L. E., Yang, M. C., Huang, S. B., Wang, S., Chen, C. H., & Wang, C. (2018). P53 enhances apoptosis induced by doxorubicin only under conditions of severe DNA damage. Cell Cycle, 17(17), 2175\u20132186. https:\/\/doi.org\/10.1080\/15384101.2018.1520565","journal-title":"Cell Cycle"},{"issue":"6","key":"9952_CR63","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/cbin.11137","volume":"43","author":"MS D'Arcy","year":"2019","unstructured":"D\u2019Arcy, M. S. (2019). Cell death: A review of the major forms of apoptosis, necrosis and autophagy. Cell Biology International, 43(6), 582\u2013592. https:\/\/doi.org\/10.1002\/cbin.11137","journal-title":"Cell Biology International"},{"issue":"7","key":"9952_CR64","doi-asserted-by":"publisher","first-page":"119039","DOI":"10.1016\/j.bbamcr.2021.119039","volume":"1868","author":"AK Bagchi","year":"2021","unstructured":"Bagchi, A. K., Malik, A., Akolkar, G., Zimmer, A., Bell\u00f3-Klein, A., De Angelis, K., Jassal, D. S., Fini, M. A., Stenmark, K. R., & Singal, P. K. (2021). Study of ER stress and apoptotic proteins in the heart and tumor exposed to doxorubicin. Biochimica et Biophysica Acta (BBA) Molecular Cell Research, 1868(7), 119039. https:\/\/doi.org\/10.1016\/j.bbamcr.2021.119039","journal-title":"Biochimica et Biophysica Acta (BBA) Molecular Cell Research"},{"key":"9952_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10121897","author":"AK Bagchi","year":"2021","unstructured":"Bagchi, A. K., Malik, A., Akolkar, G., Jassal, D. S., & Singal, P. K. (2021). Endoplasmic reticulum stress promotes iNOS\/NO and influences inflammation in the development of doxorubicin-induced cardiomyopathy. Antioxidants (Basel). https:\/\/doi.org\/10.3390\/antiox10121897","journal-title":"Antioxidants (Basel)"},{"key":"9952_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314649","author":"A Bhagat","year":"2022","unstructured":"Bhagat, A., Shrestha, P., & Kleinerman, E. S. (2022). The innate immune system in cardiovascular diseases and its role in doxorubicin-induced cardiotoxicity. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms232314649","journal-title":"International Journal of Molecular Sciences"},{"key":"9952_CR67","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.toxlet.2017.04.010","volume":"276","author":"RC Chen","year":"2017","unstructured":"Chen, R. C., Sun, G. B., Ye, J. X., Wang, J., Zhang, M. D., & Sun, X. B. (2017). Salvianolic acid B attenuates doxorubicin-induced ER stress by inhibiting TRPC3 and TRPC6 mediated Ca(2+) overload in rat cardiomyocytes. Toxicology Letters, 276, 21\u201330. https:\/\/doi.org\/10.1016\/j.toxlet.2017.04.010","journal-title":"Toxicology Letters"},{"key":"9952_CR68","doi-asserted-by":"publisher","first-page":"109475","DOI":"10.1016\/j.biopha.2019.109475","volume":"120","author":"J Hu","year":"2019","unstructured":"Hu, J., Wu, Q., Wang, Z., Hong, J., Chen, R., Li, B., Hu, Z., Hu, X., & Zhang, M. (2019). Inhibition of CACNA1H attenuates doxorubicin-induced acute cardiotoxicity by affecting endoplasmic reticulum stress. Biomedicine & Pharmacotherapy, 120, 109475. https:\/\/doi.org\/10.1016\/j.biopha.2019.109475","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"9952_CR69","doi-asserted-by":"publisher","first-page":"110412","DOI":"10.1016\/j.cellsig.2022.110412","volume":"98","author":"SW Kim","year":"2022","unstructured":"Kim, S. W., Ahn, B.-Y., Tran, T. T. V., Pyun, J.-H., Kang, J.-S., & Leem, Y.-E. (2022). PRMT1 suppresses doxorubicin-induced cardiotoxicity by inhibiting endoplasmic reticulum stress. Cellular Signalling, 98, 110412. https:\/\/doi.org\/10.1016\/j.cellsig.2022.110412","journal-title":"Cellular Signalling"},{"key":"9952_CR70","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.tox.2013.04.016","volume":"309","author":"BJN Sishi","year":"2013","unstructured":"Sishi, B. J. N., Loos, B., van Rooyen, J., & Engelbrecht, A.-M. (2013). Doxorubicin induces protein ubiquitination and inhibits proteasome activity during cardiotoxicity. Toxicology, 309, 23\u201329. https:\/\/doi.org\/10.1016\/j.tox.2013.04.016","journal-title":"Toxicology"},{"key":"9952_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-physiol-021317-121427","volume":"80","author":"S Sciarretta","year":"2018","unstructured":"Sciarretta, S., Maejima, Y., Zablocki, D., & Sadoshima, J. (2018). The role of autophagy in the heart. Annual Review of Physiology, 80, 1\u201326. https:\/\/doi.org\/10.1146\/annurev-physiol-021317-121427","journal-title":"Annual Review of Physiology"},{"issue":"28","key":"9952_CR72","doi-asserted-by":"publisher","first-page":"46663","DOI":"10.18632\/oncotarget.16944","volume":"8","author":"N Koleini","year":"2017","unstructured":"Koleini, N., & Kardami, E. (2017). Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity. Oncotarget, 8(28), 46663\u201346680. https:\/\/doi.org\/10.18632\/oncotarget.16944","journal-title":"Oncotarget"},{"issue":"2","key":"9952_CR73","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10557-020-06941-x","volume":"34","author":"KN Timm","year":"2020","unstructured":"Timm, K. N., & Tyler, D. J. (2020). The role of AMPK activation for cardioprotection in doxorubicin-induced cardiotoxicity. Cardiovascular Drugs and Therapy, 34(2), 255\u2013269. https:\/\/doi.org\/10.1007\/s10557-020-06941-x","journal-title":"Cardiovascular Drugs and Therapy"},{"issue":"1","key":"9952_CR74","doi-asserted-by":"publisher","first-page":"H37","DOI":"10.1152\/ajpheart.01057.2004","volume":"289","author":"M Tokarska-Schlattner","year":"2005","unstructured":"Tokarska-Schlattner, M., Zaugg, M., da Silva, R., Lucchinetti, E., Schaub, M. C., Wallimann, T., & Schlattner, U. (2005). Acute toxicity of doxorubicin on isolated perfused heart: Response of kinases regulating energy supply. American Journal of Physiology. Heart and Circulatory Physiology, 289(1), H37-47. https:\/\/doi.org\/10.1152\/ajpheart.01057.2004","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"issue":"3\u20134","key":"9952_CR75","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ejps.2010.07.015","volume":"41","author":"DR Barpe","year":"2010","unstructured":"Barpe, D. R., Rosa, D. D., & Froehlich, P. E. (2010). Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. European Journal of Pharmaceutical Sciences, 41(3\u20134), 458\u2013463. https:\/\/doi.org\/10.1016\/j.ejps.2010.07.015","journal-title":"European Journal of Pharmaceutical Sciences"},{"issue":"3","key":"9952_CR76","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/cvr\/cvs134","volume":"95","author":"S Gratia","year":"2012","unstructured":"Gratia, S., Kay, L., Potenza, L., Seffouh, A., Novel-Chat\u00e9, V., Schnebelen, C., Sestili, P., Schlattner, U., & Tokarska-Schlattner, M. (2012). Inhibition of AMPK signalling by doxorubicin: At the crossroads of the cardiac responses to energetic, oxidative, and genotoxic stress. Cardiovascular Research, 95(3), 290\u2013299. https:\/\/doi.org\/10.1093\/cvr\/cvs134","journal-title":"Cardiovascular Research"},{"issue":"8","key":"9952_CR77","doi-asserted-by":"publisher","first-page":"4839","DOI":"10.1074\/jbc.M113.496315","volume":"289","author":"W Yang","year":"2014","unstructured":"Yang, W., Park, I. J., Yun, H., Im, D. U., Ock, S., Kim, J., Seo, S. M., Shin, H. Y., Viollet, B., Kang, I., Choe, W., Kim, S. S., & Ha, J. (2014). AMP-activated protein kinase \u03b12 and E2F1 transcription factor mediate doxorubicin-induced cytotoxicity by forming a positive signal loop in mouse embryonic fibroblasts and non-carcinoma cells. Journal of Biological Chemistry, 289(8), 4839\u20134852. https:\/\/doi.org\/10.1074\/jbc.M113.496315","journal-title":"Journal of Biological Chemistry"},{"issue":"2","key":"9952_CR78","doi-asserted-by":"publisher","first-page":"e018393","DOI":"10.1161\/JAHA.119.018393","volume":"10","author":"H Abdel-Qadir","year":"2021","unstructured":"Abdel-Qadir, H., Bobrowski, D., Zhou, L., Austin, P. C., Calvillo-Arg\u00fcelles, O., Amir, E., Lee, D. S., & Thavendiranathan, P. (2021). Statin exposure and risk of heart failure after anthracycline- or trastuzumab-based chemotherapy for early breast cancer: a propensity score-matched cohort study. Journal of the American Heart Association, 10(2), e018393. https:\/\/doi.org\/10.1161\/JAHA.119.018393","journal-title":"Journal of the American Heart Association"},{"key":"9952_CR79","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2200097","author":"WG Hundley","year":"2022","unstructured":"Hundley, W. G., D\u2019Agostino, R., Jr., Crotts, T., Craver, K., Hackney, M. H., Jordan, J. H., Ky, B., Wagner, L. I., Herrington, D. M., Yeboah, J., Reding, K. W., Ladd, A. C., Rapp, S. R., Russo, S., O\u2019Connell, N., Weaver, K. E., Dressler, E. V., Ge, Y., Melin, S. A., \u2026 Lesser, G. J. (2022). Statins and left ventricular ejection fraction following doxorubicin treatment. NEJM Evidence. https:\/\/doi.org\/10.1056\/evidoa2200097","journal-title":"NEJM Evidence"},{"issue":"1","key":"9952_CR80","doi-asserted-by":"publisher","first-page":"12759","DOI":"10.1038\/s41598-023-40061-4","volume":"13","author":"N Osataphan","year":"2023","unstructured":"Osataphan, N., Phrommintikul, A., Leemasawat, K., Somwangprasert, A., Apaijai, N., Suksai, S., Sirikul, W., Gunaparn, S., Chattipakorn, S. C., & Chattipakorn, N. (2023). Effects of metformin and donepezil on the prevention of doxorubicin-induced cardiotoxicity in breast cancer: A randomized controlled trial. Scientific Reports, 13(1), 12759. https:\/\/doi.org\/10.1038\/s41598-023-40061-4","journal-title":"Scientific Reports"},{"issue":"8","key":"9952_CR81","doi-asserted-by":"publisher","first-page":"e104888","DOI":"10.1371\/journal.pone.0104888","volume":"9","author":"LC Kobashigawa","year":"2014","unstructured":"Kobashigawa, L. C., Xu, Y. C., Padbury, J. F., Tseng, Y. T., & Yano, N. (2014). Metformin protects cardiomyocyte from doxorubicin induced cytotoxicity through an AMP-activated protein kinase dependent signaling pathway: An in vitro study. PLoS ONE, 9(8), e104888. https:\/\/doi.org\/10.1371\/journal.pone.0104888","journal-title":"PLoS ONE"},{"issue":"2","key":"9952_CR82","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3892\/mmr.2015.4665","volume":"13","author":"MH Liu","year":"2016","unstructured":"Liu, M. H., Lin, X. L., Guo, D. M., Zhang, Y., Yuan, C., Tan, T. P., Chen, Y. D., Wu, S. J., Ye, Z. F., & He, J. (2016). Resveratrol protects cardiomyocytes from doxorubicin-induced apoptosis through the AMPK\/P53 pathway. Molecular Medicine Reports, 13(2), 1281\u20131286. https:\/\/doi.org\/10.3892\/mmr.2015.4665","journal-title":"Molecular Medicine Reports"},{"issue":"1","key":"9952_CR83","doi-asserted-by":"publisher","first-page":"H39","DOI":"10.1152\/ajpheart.00008.2019","volume":"317","author":"R Li","year":"2019","unstructured":"Li, R., Huang, Y., Semple, I., Kim, M., Zhang, Z., & Lee, J. H. (2019). Cardioprotective roles of sestrin 1 and sestrin 2 against doxorubicin cardiotoxicity. American Journal of Physiology. Heart and Circulatory Physiology, 317(1), H39-h48. https:\/\/doi.org\/10.1152\/ajpheart.00008.2019","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"9952_CR84","doi-asserted-by":"publisher","first-page":"6797","DOI":"10.26355\/eurrev_202111_27124","volume":"25","author":"V Quagliariello","year":"2021","unstructured":"Quagliariello, V., Paccone, A., Iovine, M., Cavalcanti, E., Berretta, M., Maurea, C., Canale, M. L., & Maurea, N. (2021). Interleukin-1 blocking agents as promising strategy for prevention of anticancer drug-induced cardiotoxicities: Possible implications in cancer patients with COVID-19. European Review for Medical & Pharmacological Sciences, 25, 6797\u20136812. https:\/\/doi.org\/10.26355\/eurrev_202111_27124","journal-title":"European Review for Medical & Pharmacological Sciences"},{"issue":"7","key":"9952_CR85","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.biopha.2011.06.005","volume":"65","author":"J Zhu","year":"2011","unstructured":"Zhu, J., Zhang, J., Zhang, L., Du, R., Xiang, D., Wu, M., Zhang, R., & Han, W. (2011). Interleukin-1 signaling mediates acute doxorubicin-induced cardiotoxicity. Biomedicine & Pharmacotherapy, 65(7), 481\u2013485. https:\/\/doi.org\/10.1016\/j.biopha.2011.06.005","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"9952_CR86","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.yjmcc.2019.08.009","volume":"136","author":"L Meng","year":"2019","unstructured":"Meng, L., Lin, H., Zhang, J., Lin, N., Sun, Z., Gao, F., Luo, H., Ni, T., Luo, W., Chi, J., & Guo, H. (2019). Doxorubicin induces cardiomyocyte pyroptosis via the TINCR-mediated posttranscriptional stabilization of NLR family pyrin domain containing 3. Journal of Molecular and Cellular Cardiology, 136, 15\u201326. https:\/\/doi.org\/10.1016\/j.yjmcc.2019.08.009","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"9952_CR87","doi-asserted-by":"crossref","unstructured":"Quagliariello, V., De Laurentiis, M., Cocco, S., Rea, G., Bonelli, A., Caronna, A., Lombari, M. C., Conforti, G., Berretta, M., Botti, G., & Maurea, N. (2020). NLRP3 as putative marker of ipilimumab-induced cardiotoxicity in the presence of hyperglycemia in estrogen-responsive and triple-negative breast cancer cells. International Journal of Molecular Sciences, 21(20), 7802. https:\/\/www.mdpi.com\/1422-0067\/21\/20\/7802","DOI":"10.3390\/ijms21207802"},{"key":"9952_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biopha.2018.11.042","volume":"110","author":"S Gioffr\u00e9","year":"2019","unstructured":"Gioffr\u00e9, S., Ricci, V., Vavassori, C., Ruggeri, C., Chiesa, M., Alfieri, I., Zorzan, S., Buzzetti, M., Milano, G., Scopece, A., Castiglioni, L., Sironi, L., Pompilio, G., Colombo, G. I., & D\u2019Alessandra, Y. (2019). Plasmatic and chamber-specific modulation of cardiac microRNAs in an acute model of DOX-induced cardiotoxicity. Biomedicine & Pharmacotherapy, 110, 1\u20138. https:\/\/doi.org\/10.1016\/j.biopha.2018.11.042","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"9952_CR89","doi-asserted-by":"publisher","first-page":"9282484","DOI":"10.1155\/2022\/9282484","volume":"2022","author":"C Zhu","year":"2022","unstructured":"Zhu, C., Dong, X., Wang, X., Zheng, Y., Qiu, J., Peng, Y., Xu, J., Chai, Z., & Liu, C. (2022). Multiple roles of SIRT2 in regulating physiological and pathological signal transduction. Genet Res (Camb), 2022, 9282484. https:\/\/doi.org\/10.1155\/2022\/9282484","journal-title":"Genet Res (Camb)"},{"issue":"9","key":"9952_CR90","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/s41418-018-0069-8","volume":"25","author":"M Sarikhani","year":"2018","unstructured":"Sarikhani, M., Mishra, S., Desingu, P. A., Kotyada, C., Wolfgeher, D., Gupta, M. P., Singh, M., & Sundaresan, N. R. (2018). SIRT2 regulates oxidative stress-induced cell death through deacetylation of c-Jun NH(2)-terminal kinase. Cell Death and Differentiation, 25(9), 1638\u20131656. https:\/\/doi.org\/10.1038\/s41418-018-0069-8","journal-title":"Cell Death and Differentiation"},{"issue":"4","key":"9952_CR91","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/carcin\/bgaa039","volume":"41","author":"F He","year":"2020","unstructured":"He, F., Antonucci, L., & Karin, M. (2020). NRF2 as a regulator of cell metabolism and inflammation in cancer. Carcinogenesis, 41(4), 405\u2013416. https:\/\/doi.org\/10.1093\/carcin\/bgaa039","journal-title":"Carcinogenesis"},{"key":"9952_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21134777","author":"F He","year":"2020","unstructured":"He, F., Ru, X., & Wen, T. (2020). NRF2, a transcription factor for stress response and beyond. International journal of molecular sciences. https:\/\/doi.org\/10.3390\/ijms21134777","journal-title":"International journal of molecular sciences"},{"key":"9952_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27082416","author":"Q Chen","year":"2022","unstructured":"Chen, Q., Yu, M., Tian, Z., Cui, Y., Deng, D., Rong, T., Liu, Z., Song, M., Li, Z., Ma, X., & Lu, H. (2022). Exogenous glutathione protects IPEC-J2 cells against oxidative stress through a mitochondrial mechanism. Molecules. https:\/\/doi.org\/10.3390\/molecules27082416","journal-title":"Molecules"},{"key":"9952_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/ph14111188","author":"AM Kabel","year":"2021","unstructured":"Kabel, A. M., Salama, S. A., Adwas, A. A., & Estfanous, R. S. (2021). Targeting oxidative stress, NLRP3 inflammasome, and autophagy by fraxetin to combat doxorubicin-induced cardiotoxicity. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph14111188","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"9952_CR95","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1161\/circresaha.119.316061","volume":"127","author":"D Han","year":"2020","unstructured":"Han, D., Wang, Y., Wang, Y., Dai, X., Zhou, T., Chen, J., Tao, B., Zhang, J., & Cao, F. (2020). The tumor-suppressive human circular RNA CircITCH sponges miR-330-5p to ameliorate doxorubicin-induced cardiotoxicity through upregulating SIRT6, survivin, and SERCA2a. Circulation Research, 127(4), e108\u2013e125. https:\/\/doi.org\/10.1161\/circresaha.119.316061","journal-title":"Circulation Research"},{"key":"9952_CR96","doi-asserted-by":"publisher","first-page":"737826","DOI":"10.3389\/fcvm.2021.737826","volume":"8","author":"J Henderson","year":"2021","unstructured":"Henderson, J., Dubey, P. K., Patil, M., Singh, S., Dubey, S., Namakkal Soorappan, R., Kannappan, R., Sethu, P., Qin, G., Zhang, J., & Krishnamurthy, P. (2021). microRNA-377 signaling modulates anticancer drug-induced cardiotoxicity in mice. Frontiers in Cardiovascular Medicine, 8, 737826. https:\/\/doi.org\/10.3389\/fcvm.2021.737826","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"9","key":"9952_CR97","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/s41419-019-1901-x","volume":"10","author":"JA Pan","year":"2019","unstructured":"Pan, J. A., Tang, Y., Yu, J. Y., Zhang, H., Zhang, J. F., Wang, C. Q., & Gu, J. (2019). miR-146a attenuates apoptosis and modulates autophagy by targeting TAF9b\/P53 pathway in doxorubicin-induced cardiotoxicity. Cell Death & Disease, 10(9), 668. https:\/\/doi.org\/10.1038\/s41419-019-1901-x","journal-title":"Cell Death & Disease"},{"issue":"8","key":"9952_CR98","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1002\/tox.23551","volume":"37","author":"Y Liu","year":"2022","unstructured":"Liu, Y., Tan, L., Zhang, M., & Yang, C. (2022). Long noncoding RNA TDRG1 aggravates doxorubicin-induced cardiomyopathy by binding with miR-873-5p to upregulate PRKAR2. Environmental Toxicology, 37(8), 2072\u20132083. https:\/\/doi.org\/10.1002\/tox.23551","journal-title":"Environmental Toxicology"},{"issue":"2","key":"9952_CR99","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1159\/000491896","volume":"48","author":"X Jing","year":"2018","unstructured":"Jing, X., Yang, J., Jiang, L., Chen, J., & Wang, H. (2018). MicroRNA-29b regulates the mitochondria-dependent apoptotic pathway by targeting bax in doxorubicin cardiotoxicity. Cellular Physiology and Biochemistry, 48(2), 692\u2013704. https:\/\/doi.org\/10.1159\/000491896","journal-title":"Cellular Physiology and Biochemistry"},{"issue":"3","key":"9952_CR100","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s12012-016-9393-8","volume":"17","author":"J Novak","year":"2017","unstructured":"Novak, J., Sana, J., Stracina, T., Novakova, M., & Slaby, O. (2017). Doxorubicin and liposomal doxorubicin differentially affect expression of miR-208a and let-7g in Rat ventricles and Atria. Cardiovascular Toxicology, 17(3), 355\u2013359. https:\/\/doi.org\/10.1007\/s12012-016-9393-8","journal-title":"Cardiovascular Toxicology"},{"key":"9952_CR101","doi-asserted-by":"publisher","first-page":"740515","DOI":"10.3389\/fcvm.2021.740515","volume":"8","author":"L Chen","year":"2021","unstructured":"Chen, L., & Xu, Y. (2021). MicroRNAs as biomarkers and therapeutic targets in doxorubicin-induced cardiomyopathy: a review. Frontiers in Cardiovascular Medicine, 8, 740515. https:\/\/doi.org\/10.3389\/fcvm.2021.740515","journal-title":"Frontiers in Cardiovascular Medicine"},{"key":"9952_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25235672","author":"B Almeida","year":"2020","unstructured":"Almeida, B., Nag, O. K., Rogers, K. E., & Delehanty, J. B. (2020). Recent progress in bioconjugation strategies for liposome-mediated drug delivery. Molecules. https:\/\/doi.org\/10.3390\/molecules25235672","journal-title":"Molecules"},{"issue":"1","key":"9952_CR103","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1631\/jzus.B1600303","volume":"18","author":"M Zhao","year":"2017","unstructured":"Zhao, M., Ding, X. F., Shen, J. Y., Zhang, X. P., Ding, X. W., & Xu, B. (2017). Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice. Journal of Zhejiang University. Science. B, 18(1), 15\u201326. https:\/\/doi.org\/10.1631\/jzus.B1600303","journal-title":"Journal of Zhejiang University. Science. B"},{"key":"9952_CR104","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174421","author":"F Schettini","year":"2021","unstructured":"Schettini, F., Giuliano, M., Lambertini, M., Bartsch, R., Pinato, D. J., Onesti, C. E., Harbeck, N., L\u00fcftner, D., Rottey, S., van Dam, P. A., Zaman, K., Mustacchi, G., Gligorov, J., Awada, A., Campone, M., Wildiers, H., Gennari, A., Tjan-Heijnen, V. C. G., Cortes, J., \u2026 Generali, D. (2021). Anthracyclines strike back: Rediscovering non-pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13174421","journal-title":"Cancers (Basel)"},{"key":"9952_CR105","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijpharm.2018.12.077","volume":"558","author":"HH Peng","year":"2019","unstructured":"Peng, H. H., Hong, D. X., Guan, Y. X., & Yao, S. J. (2019). Preparation of pH-responsive DOX-loaded chitosan nanoparticles using supercritical assisted atomization with an enhanced mixer. International Journal of Pharmaceutics, 558, 82\u201390. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.12.077","journal-title":"International Journal of Pharmaceutics"},{"issue":"3","key":"9952_CR106","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1124\/pr.115.012070","volume":"68","author":"P Yingchoncharoen","year":"2016","unstructured":"Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016). Lipid-based drug delivery systems in cancer therapy: What Is available and what is yet to come. Pharmacological Reviews, 68(3), 701\u2013787. https:\/\/doi.org\/10.1124\/pr.115.012070","journal-title":"Pharmacological Reviews"},{"key":"9952_CR107","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3389\/fphar.2019.00669","volume":"10","author":"M Robella","year":"2019","unstructured":"Robella, M., Vaira, M., Argenziano, M., Spagnolo, R., Cavalli, R., Borsano, A., Gentilli, S., & De Simone, M. (2019). Exploring the use of pegylated liposomal doxorubicin (Caelyx(\u00ae)) as pressurized intraperitoneal aerosol chemotherapy. Frontiers in Pharmacology, 10, 669. https:\/\/doi.org\/10.3389\/fphar.2019.00669","journal-title":"Frontiers in Pharmacology"},{"key":"9952_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27031086","author":"D Sivadasan","year":"2022","unstructured":"Sivadasan, D., Sultan, M. H., Madkhali, O. A., Alsabei, S. H., & Alessa, A. A. (2022). Stealth liposomes (PEGylated) containing an anticancer drug camptothecin: In vitro characterization and in vivo pharmacokinetic and tissue distribution study. Molecules. https:\/\/doi.org\/10.3390\/molecules27031086","journal-title":"Molecules"},{"key":"9952_CR109","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19061615","author":"YT Chiang","year":"2018","unstructured":"Chiang, Y. T., Lyu, S. Y., Wen, Y. H., & Lo, C. L. (2018). Preparation and characterization of electrostatically crosslinked polymer\u207bliposomes in anticancer therapy. International journal of molecular sciences. https:\/\/doi.org\/10.3390\/ijms19061615","journal-title":"International journal of molecular sciences"},{"key":"9952_CR110","doi-asserted-by":"publisher","DOI":"10.4172\/2157-7439.1000519","author":"N Zhao","year":"2018","unstructured":"Zhao, N., Woodle, M. C., & Mixson, A. J. (2018). Advances in delivery systems for doxorubicin. Journal of nanomedicine & nanotechnology. https:\/\/doi.org\/10.4172\/2157-7439.1000519","journal-title":"Journal of nanomedicine & nanotechnology"},{"issue":"9","key":"9952_CR111","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1097\/cad.0000000000000811","volume":"30","author":"C Zhang","year":"2019","unstructured":"Zhang, C., Yao, H., Kong, P. Y., Liu, Y., Gao, L., Gao, L., Ma, Y. Y., Liu, J., Tan, X., & Zhang, X. (2019). Pegylated liposomal doxorubicin for myeloid neoplasms. Anti-Cancer Drugs, 30(9), 948\u2013952. https:\/\/doi.org\/10.1097\/cad.0000000000000811","journal-title":"Anti-Cancer Drugs"},{"issue":"3","key":"9952_CR112","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/cad.0000000000000182","volume":"26","author":"E Tahover","year":"2015","unstructured":"Tahover, E., Patil, Y. P., & Gabizon, A. A. (2015). Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: Focus on liposomes. Anti-Cancer Drugs, 26(3), 241\u2013258. https:\/\/doi.org\/10.1097\/cad.0000000000000182","journal-title":"Anti-Cancer Drugs"},{"key":"9952_CR113","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2147\/bctt.S170239","volume":"10","author":"YL Franco","year":"2018","unstructured":"Franco, Y. L., Vaidya, T. R., & Ait-Oudhia, S. (2018). Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer. Breast Cancer (Dove Med Press), 10, 131\u2013141. https:\/\/doi.org\/10.2147\/bctt.S170239","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"1","key":"9952_CR114","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1146\/annurev-virology-092818-015756","volume":"6","author":"JW Schoggins","year":"2019","unstructured":"Schoggins, J. W. (2019). Interferon-stimulated genes: What do they all do? Annual Review of Virology, 6(1), 567\u2013584. https:\/\/doi.org\/10.1146\/annurev-virology-092818-015756","journal-title":"Annual Review of Virology"},{"issue":"5","key":"9952_CR115","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/cvr\/cvz192","volume":"116","author":"M Gy\u00f6ngy\u00f6si","year":"2020","unstructured":"Gy\u00f6ngy\u00f6si, M., Lukovic, D., Zlabinger, K., Spannbauer, A., Gugerell, A., Pavo, N., Traxler, D., Pils, D., Maurer, G., Jakab, A., Riesenhuber, M., Pircher, A., Winkler, J., & Bergler-Klein, J. (2020). Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance. Cardiovascular Research, 116(5), 970\u2013982. https:\/\/doi.org\/10.1093\/cvr\/cvz192","journal-title":"Cardiovascular Research"},{"key":"9952_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.003","volume":"105","author":"D Morin","year":"2016","unstructured":"Morin, D., Musman, J., Pons, S., Berdeaux, A., & Ghaleh, B. (2016). Mitochondrial translocator protein (TSPO): From physiology to cardioprotection. Biochemical Pharmacology, 105, 1\u201313. https:\/\/doi.org\/10.1016\/j.bcp.2015.12.003","journal-title":"Biochemical Pharmacology"},{"key":"9952_CR117","doi-asserted-by":"publisher","first-page":"116677","DOI":"10.1016\/j.lfs.2019.116677","volume":"232","author":"M Fallah","year":"2019","unstructured":"Fallah, M., Mohammadi, H., Shaki, F., Hosseini-Khah, Z., Moloudizargari, M., Dashti, A., Ziar, A., Mohammadpour, A., Mirshafa, A., Modanloo, M., & Shokrzadeh, M. (2019). Doxorubicin and liposomal doxorubicin induce senescence by enhancing nuclear factor kappa B and mitochondrial membrane potential. Life Sciences, 232, 116677. https:\/\/doi.org\/10.1016\/j.lfs.2019.116677","journal-title":"Life Sciences"},{"issue":"1","key":"9952_CR118","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13104-018-3260-6","volume":"11","author":"C Stark","year":"2018","unstructured":"Stark, C., Taimen, P., Savunen, T., & Koskenvuo, J. (2018). Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice. BMC Research Notes, 11(1), 148. https:\/\/doi.org\/10.1186\/s13104-018-3260-6","journal-title":"BMC Research Notes"},{"issue":"6","key":"9952_CR119","doi-asserted-by":"publisher","first-page":"3600","DOI":"10.3892\/or.2016.4748","volume":"35","author":"C Sun","year":"2016","unstructured":"Sun, C., Zhou, L., Gou, M., Shi, S., Li, T., & Lang, J. (2016). Improved antitumor activity and reduced myocardial toxicity of doxorubicin encapsulated in MPEG-PCL nanoparticles. Oncology Reports, 35(6), 3600\u20133606. https:\/\/doi.org\/10.3892\/or.2016.4748","journal-title":"Oncology Reports"},{"issue":"9","key":"9952_CR120","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s11095-017-2194-3","volume":"34","author":"K Razavi-Azarkhiavi","year":"2017","unstructured":"Razavi-Azarkhiavi, K., Jaafari, M. R., Abnous, K., Razavi, B. M., Jafarian, A. H., Hassani, F. V., Shirani, K., & Karimi, G. (2017). The cardiotoxic mechanism of doxorubicin (DOX) and pegylated liposomal DOX in mice bearing C-26 colon carcinoma: A study focused on microRNA role for toxicity assessment of new formulations. Pharmaceutical Research, 34(9), 1849\u20131856. https:\/\/doi.org\/10.1007\/s11095-017-2194-3","journal-title":"Pharmaceutical Research"},{"issue":"2","key":"9952_CR121","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00280-008-0887-3","volume":"64","author":"P Schmid","year":"2009","unstructured":"Schmid, P., Krocker, J., Kreienberg, R., Klare, P., Kittel, K., Sommer, H., Heinrich, G., Steck, T., Lichtenegger, W., Elling, D., & K\u00fcmmel, S. (2009). Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: Final results of a phase II trial. Cancer Chemotherapy and Pharmacology, 64(2), 401\u2013406. https:\/\/doi.org\/10.1007\/s00280-008-0887-3","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"3","key":"9952_CR122","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"ME O'Brien","year":"2004","unstructured":"O\u2019Brien, M. E., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., Orlandi, F., Mellars, L., Alland, L., & Tendler, C. (2004). Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Annals of Oncology, 15(3), 440\u2013449. https:\/\/doi.org\/10.1093\/annonc\/mdh097","journal-title":"Annals of Oncology"},{"issue":"1","key":"9952_CR123","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/annonc\/mdq319","volume":"22","author":"C Rochlitz","year":"2011","unstructured":"Rochlitz, C., Ruhstaller, T., Lerch, S., Spirig, C., Huober, J., Suter, T., B\u00fchlmann, M., Fehr, M., Sch\u00f6nenberger, A., von Moos, R., Winterhalder, R., Rauch, D., M\u00fcller, A., Mannhart-Harms, M., Herrmann, R., Cliffe, B., Mayer, M., & Zaman, K. (2011). Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24\/06). Annals of oncology, 22(1), 80\u201385. https:\/\/doi.org\/10.1093\/annonc\/mdq319","journal-title":"Annals of oncology"},{"issue":"9","key":"9952_CR124","doi-asserted-by":"publisher","first-page":"e44837","DOI":"10.7759\/cureus.44837","volume":"15","author":"M Alhaja","year":"2023","unstructured":"Alhaja, M., Chen, S., Chin, A. C., Schulte, B., & Legasto, C. S. (2023). Cardiac safety of pegylated liposomal doxorubicin after conventional doxorubicin exposure in patients with sarcoma and breast cancer. Cureus, 15(9), e44837. https:\/\/doi.org\/10.7759\/cureus.44837","journal-title":"Cureus"},{"key":"9952_CR125","doi-asserted-by":"crossref","unstructured":"Quagliariello, V., Berretta, M., Bisceglia, I., Giacobbe, I., Iovine, M., Giordano, V., Arianna, R., Barbato, M., Izzo, F., Maurea, C., Canale, M. L., Paccone, A., Inno, A., Scherillo, M., Gabrielli, D., & Maurea, N. (2024). The sGCa Vericiguat Exhibit Cardioprotective and Anti-Sarcopenic Effects through NLRP-3 Pathways: Potential Benefits for Anthracycline-Treated Cancer Patients. Cancers, 16(8), 1487. https:\/\/www.mdpi.com\/2072-6694\/16\/8\/1487","DOI":"10.3390\/cancers16081487"},{"issue":"5","key":"9952_CR126","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jaccao.2020.09.007","volume":"2","author":"NE Boutagy","year":"2020","unstructured":"Boutagy, N. E., Feher, A., Pfau, D., Liu, Z., Guerrera, N. M., Freeburg, L. A., Womack, S. J., Hoenes, A. C., Zeiss, C., Young, L. H., Spinale, F. G., & Sinusas, A. J. (2020). Dual angiotensin receptor-neprilysin inhibition with sacubitril\/valsartan attenuates systolic dysfunction in experimental doxorubicin-induced cardiotoxicity. JACC CardioOncol, 2(5), 774\u2013787. https:\/\/doi.org\/10.1016\/j.jaccao.2020.09.007","journal-title":"JACC CardioOncol"},{"issue":"6","key":"9952_CR127","doi-asserted-by":"publisher","first-page":"339","DOI":"10.14744\/AnatolJCardiol.2023.2825","volume":"27","author":"S Ulusan","year":"2023","unstructured":"Ulusan, S., G\u00fclle, K., Peynirci, A., Sevimli, M., Karaibrahimoglu, A., & Kuyumcu, M. S. (2023). Dapagliflozin may protect against doxorubicin-induced cardiotoxicity. Anatolian journal of cardiology, 27(6), 339\u2013347. https:\/\/doi.org\/10.14744\/AnatolJCardiol.2023.2825","journal-title":"Anatolian journal of cardiology"},{"issue":"1","key":"9952_CR128","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","volume":"20","author":"V Quagliariello","year":"2021","unstructured":"Quagliariello, V., De Laurentiis, M., Rea, D., Barbieri, A., Monti, M. G., Carbone, A., Paccone, A., Altucci, L., Conte, M., Canale, M. L., Botti, G., & Maurea, N. (2021). The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovascular Diabetology, 20(1), 150. https:\/\/doi.org\/10.1186\/s12933-021-01346-y","journal-title":"Cardiovascular Diabetology"},{"issue":"1","key":"9952_CR129","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s43046-020-00034-4","volume":"32","author":"SM Khallaf","year":"2020","unstructured":"Khallaf, S. M., Roshdy, J., & Ibrahim, A. (2020). Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center. Journal of the Egyptian National Cancer Institute, 32(1), 20. https:\/\/doi.org\/10.1186\/s43046-020-00034-4","journal-title":"Journal of the Egyptian National Cancer Institute"},{"issue":"16","key":"9952_CR130","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1016\/j.ejca.2015.07.031","volume":"51","author":"N Yamaguchi","year":"2015","unstructured":"Yamaguchi, N., Fujii, T., Aoi, S., Kozuch, P. S., Hortobagyi, G. N., & Blum, R. H. (2015). Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: A Bayesian network meta-analysis. European Journal of Cancer, 51(16), 2314\u20132320. https:\/\/doi.org\/10.1016\/j.ejca.2015.07.031","journal-title":"European Journal of Cancer"},{"key":"9952_CR131","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-1-10","author":"SM Rafiyath","year":"2012","unstructured":"Rafiyath, S. M., Rasul, M., Lee, B., Wei, G., Lamba, G., & Liu, D. (2012). Comparison of safety and toxicity of liposomal doxorubicin vs. Conventional anthracyclines: A meta-analysis. Experimental hematology & oncology. https:\/\/doi.org\/10.1186\/2162-3619-1-10","journal-title":"Experimental hematology & oncology"},{"key":"9952_CR132","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.breast.2020.09.001","volume":"54","author":"I Blancas","year":"2020","unstructured":"Blancas, I., Mart\u00edn-P\u00e9rez, F. J., Garrido, J. M., & Rodr\u00edguez-Serrano, F. (2020). NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients. Breast, 54, 106\u2013113. https:\/\/doi.org\/10.1016\/j.breast.2020.09.001","journal-title":"Breast"},{"issue":"3","key":"9952_CR133","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.ijcard.2012.10.079","volume":"167","author":"M Lotrionte","year":"2013","unstructured":"Lotrionte, M., Palazzoni, G., Abbate, A., De Marco, E., Mezzaroma, E., Di Persio, S., Frati, G., Loperfido, F., & Biondi-Zoccai, G. (2013). Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: The LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study. International Journal of Cardiology, 167(3), 1055\u20131057. https:\/\/doi.org\/10.1016\/j.ijcard.2012.10.079","journal-title":"International Journal of Cardiology"},{"issue":"1","key":"9952_CR134","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/j.clbc.2017.10.005","volume":"18","author":"AE Chang","year":"2018","unstructured":"Chang, A. E., Wu, Q. V., Jenkins, I. C., Specht, J. M., Gadi, V. K., Gralow, J. R., Salazar, L. G., Kurland, B. F., & Linden, H. M. (2018). Phase I\/II Trial of combined pegylated liposomal doxorubicin and cyclophosphamide in metastatic breast cancer. Clinical Breast Cancer, 18(1), e143\u2013e149. https:\/\/doi.org\/10.1016\/j.clbc.2017.10.005","journal-title":"Clinical Breast Cancer"},{"issue":"1","key":"9952_CR135","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41598-020-80415-w","volume":"11","author":"W Liu","year":"2021","unstructured":"Liu, W., Chen, W., Zhang, X., Zhao, P., Fan, Z., Bi, L., Wu, D., Li, S., Yang, M., Fu, T., Song, D., Han, B., Zhao, G., Du, Y., & Shi, A. (2021). Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin. Science and Reports, 11(1), 199. https:\/\/doi.org\/10.1038\/s41598-020-80415-w","journal-title":"Science and Reports"},{"key":"9952_CR136","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.2147\/ott.S162003","volume":"11","author":"M Dong","year":"2018","unstructured":"Dong, M., Luo, L., Ying, X., Lu, X., Shen, J., Jiang, Z., & Wang, L. (2018). Comparable efficacy and less toxicity of pegylated liposomal doxorubicin versus epirubicin for neoadjuvant chemotherapy of breast cancer: A case-control study. Oncotargets and Therapy, 11, 4247\u20134252. https:\/\/doi.org\/10.2147\/ott.S162003","journal-title":"Oncotargets and Therapy"},{"issue":"3","key":"9952_CR137","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/ajco.12771","volume":"14","author":"FO Yang","year":"2018","unstructured":"Yang, F. O., Hsu, N. C., Moi, S. H., Lu, Y. C., Hsieh, C. M., Chang, K. J., Chen, D. R., Tu, C. W., Wang, H. C., & Hou, M. F. (2018). Efficacy and toxicity of pegylated liposomal doxorubicin-based chemotherapy in early-stage breast cancer: A multicenter retrospective case-control study. Asia-Pacific Journal of Clinical Oncology, 14(3), 198\u2013203. https:\/\/doi.org\/10.1111\/ajco.12771","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"key":"9952_CR138","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.breast.2016.11.006","volume":"31","author":"L Coltelli","year":"2017","unstructured":"Coltelli, L., Fontana, A., Lucchesi, S., Ginocchi, L., Bocci, G., Filidei, M., Scalese, M., Arrighi, G., Finale, C., Marcucci, L., Goletti, O., Salvadori, B., Ferrarini, I., Bona, E., Falcone, A., & Allegrini, G. (2017). Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients. Breast, 31, 186\u2013191. https:\/\/doi.org\/10.1016\/j.breast.2016.11.006","journal-title":"Breast"},{"issue":"4","key":"9952_CR139","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1080\/1120009x.2020.1746886","volume":"32","author":"J Yao","year":"2020","unstructured":"Yao, J., Pan, S., Fan, X., Jiang, X., Yang, Y., Jin, J., & Liu, Y. (2020). Pegylated liposomal doxorubicin as neoadjuvant therapy for stage II-III locally advanced breast cancer. Journal of Chemotherapy, 32(4), 202\u2013207. https:\/\/doi.org\/10.1080\/1120009x.2020.1746886","journal-title":"Journal of Chemotherapy"},{"issue":"7","key":"9952_CR140","doi-asserted-by":"publisher","first-page":"e0133569","DOI":"10.1371\/journal.pone.0133569","volume":"10","author":"M Xing","year":"2015","unstructured":"Xing, M., Yan, F., Yu, S., & Shen, P. (2015). Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled Trials. PLoS ONE, 10(7), e0133569. https:\/\/doi.org\/10.1371\/journal.pone.0133569","journal-title":"PLoS ONE"},{"key":"9952_CR141","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4236\/abcr.2020.93005","volume":"9","author":"A Refaat","year":"2020","unstructured":"Refaat, A., Mohamed, D., Ali, E., & Khallaf, S. (2020). Cardiac safety with high cumulative dose of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines. Advances in Breast Cancer Research, 9, 55\u201365.","journal-title":"Advances in Breast Cancer Research"},{"issue":"1","key":"9952_CR142","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1186\/s12885-021-09050-6","volume":"21","author":"J Zhang","year":"2021","unstructured":"Zhang, J., Jiang, H., Zhang, J., Bao, G., Zhang, G., Wang, H., & Wang, X. (2021). Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: A real-world study. BMC Cancer, 21(1), 1301. https:\/\/doi.org\/10.1186\/s12885-021-09050-6","journal-title":"BMC Cancer"},{"issue":"7\/8","key":"9952_CR143","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000500204","volume":"42","author":"Z Mao","year":"2019","unstructured":"Mao, Z., Shen, K., Zhu, L., Xu, M., Yu, F., Xue, D., Li, H., & Xue, C. (2019). Comparisons of cardiotoxicity and efficacy of anthracycline-based therapies in breast cancer: a network meta-analysis of randomized clinical trials. Oncology Research and Treatment, 42(7\/8), 405\u2013413. https:\/\/doi.org\/10.1159\/000500204","journal-title":"Oncology Research and Treatment"},{"issue":"1","key":"9952_CR144","doi-asserted-by":"publisher","first-page":"18481","DOI":"10.1038\/s41598-020-75614-4","volume":"10","author":"S Szmit","year":"2020","unstructured":"Szmit, S., Grela-Wojewoda, A., Talerczyk, M., Kufel-Grabowska, J., Streb, J., Smok-Kalwat, J., I\u017cycki, D., Chmielowska, E., Wilk, M., & Sosnowska-Pasiarska, B. (2020). Predictors of new-onset heart failure and overall survival in metastatic breast cancer patients treated with liposomal doxorubicin. Science and Reports, 10(1), 18481. https:\/\/doi.org\/10.1038\/s41598-020-75614-4","journal-title":"Science and Reports"},{"issue":"1","key":"9952_CR145","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13048-022-01029-6","volume":"15","author":"XR Li","year":"2022","unstructured":"Li, X. R., Cheng, X. H., Zhang, G. N., Wang, X. X., & Huang, J. M. (2022). Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer. Journal of Ovarian Research, 15(1), 96. https:\/\/doi.org\/10.1186\/s13048-022-01029-6","journal-title":"Journal of Ovarian Research"},{"issue":"2","key":"9952_CR146","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00280-021-04371-6","volume":"89","author":"XZ Wen","year":"2022","unstructured":"Wen, X. Z., Pan, Q. Z., Xu, B. S., Xiao, W., Weng, D. S., Zhao, J. J., Xu, H. R., Huang, Z., Niu, X. H., & Zhang, X. (2022). Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma. Cancer Chemotherapy and Pharmacology, 89(2), 209\u2013215. https:\/\/doi.org\/10.1007\/s00280-021-04371-6","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"4","key":"9952_CR147","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00277-014-2250-6","volume":"94","author":"I Wasle","year":"2015","unstructured":"Wasle, I., Gamerith, G., Kocher, F., Mondello, P., Jaeger, T., Walder, A., Auberger, J., Melchardt, T., Linkesch, W., Fiegl, M., & Mian, M. (2015). Non-pegylated liposomal doxorubicin in lymphoma: Patterns of toxicity and outcome in a large observational trial. Annals of Hematology, 94(4), 593\u2013601. https:\/\/doi.org\/10.1007\/s00277-014-2250-6","journal-title":"Annals of Hematology"},{"issue":"3","key":"9952_CR148","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.clml.2014.09.001","volume":"15","author":"Y Oki","year":"2015","unstructured":"Oki, Y., Ewer, M. S., Lenihan, D. J., Fisch, M. J., Hagemeister, F. B., Fanale, M., Romaguera, J., Pro, B., Fowler, N., Younes, A., Astrow, A. B., Huang, X., Kwak, L. W., Samaniego, F., McLaughlin, P., Neelapu, S. S., Wang, M., Fayad, L. E., Durand, J. B., & Rodriguez, M. A. (2015). Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: An open label, single arm, phase II trial. Clinical Lymphoma, Myeloma & Leukemia, 15(3), 152\u2013158. https:\/\/doi.org\/10.1016\/j.clml.2014.09.001","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"issue":"4","key":"9952_CR149","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/cam4.3730","volume":"10","author":"JM Sancho","year":"2021","unstructured":"Sancho, J. M., Fern\u00e1ndez-Alvarez, R., Gual-Capllonch, F., Gonz\u00e1lez-Garc\u00eda, E., Grande, C., Guti\u00e9rrez, N., Pe\u00f1arrubia, M. J., Batlle-L\u00f3pez, A., Gonz\u00e1lez-Barca, E., Guinea, J. M., Gimeno, E., Pe\u00f1alver, F. J., Fuertes, M., Bastos, M., Hern\u00e1ndez-Rivas, J., Moraleda, J. M., Garc\u00eda, O., Sorigu\u00e9, M., & Martin, A. (2021). R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients \u226560 years: Results of a randomized phase 2 study from the Spanish GELTAMO group. Cancer Medicine, 10(4), 1314\u20131326. https:\/\/doi.org\/10.1002\/cam4.3730","journal-title":"Cancer Medicine"},{"issue":"4","key":"9952_CR150","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1634\/theoncologist.2016-0289","volume":"22","author":"J Olivieri","year":"2017","unstructured":"Olivieri, J., Perna, G. P., Bocci, C., Montevecchi, C., Olivieri, A., Leoni, P., & Gini, G. (2017). Modern management of anthracycline-induced cardiotoxicity in lymphoma patients: Low occurrence of cardiotoxicity with comprehensive assessment and tailored substitution by nonpegylated liposomal doxorubicin. The Oncologist, 22(4), 422\u2013431. https:\/\/doi.org\/10.1634\/theoncologist.2016-0289","journal-title":"The Oncologist"},{"issue":"4","key":"9952_CR151","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/cncr.21662","volume":"106","author":"RM Rifkin","year":"2006","unstructured":"Rifkin, R. M., Gregory, S. A., Mohrbacher, A., & Hussein, M. A. (2006). Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: A Phase III multicenter randomized trial. Cancer, 106(4), 848\u2013858. https:\/\/doi.org\/10.1002\/cncr.21662","journal-title":"Cancer"},{"issue":"5","key":"9952_CR152","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/00001813-200606000-00014","volume":"17","author":"G Batist","year":"2006","unstructured":"Batist, G., Harris, L., Azarnia, N., Lee, L. W., & Daza-Ramirez, P. (2006). Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: Results of a retrospective analysis. Anti-Cancer Drugs, 17(5), 587\u2013595. https:\/\/doi.org\/10.1097\/00001813-200606000-00014","journal-title":"Anti-Cancer Drugs"},{"key":"9952_CR153","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ejca.2016.02.004","volume":"58","author":"MA Fridrik","year":"2016","unstructured":"Fridrik, M. A., Jaeger, U., Petzer, A., Willenbacher, W., Keil, F., Lang, A., Andel, J., Burgstaller, S., Krieger, O., Oberaigner, W., Sihorsch, K., & Greil, R. (2016). Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikament\u00f6se Tumortherapie AGMT](NHL-14). European Journal of Cancer, 58, 112\u2013121. https:\/\/doi.org\/10.1016\/j.ejca.2016.02.004","journal-title":"European Journal of Cancer"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-024-09952-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-024-09952-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-024-09952-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T08:54:10Z","timestamp":1739177650000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-024-09952-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":153,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["9952"],"URL":"https:\/\/doi.org\/10.1007\/s12012-024-09952-4","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"22 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}